Artelo Biosciences (ARTL) announces the publication of a peer-reviewed article, “The Emerging Role of Fatty Acid Binding Protein 3 in Cancers”, in Drug Discovery Today. The publication’s lead author is Dr. George Warren, Principal Scientist at Artelo. This publication marks the third in a trilogy of reviews exploring the protumoral roles of FABP isoforms 3, 5, and 7 in cancer biology. “Our continued investigation into FABPs demonstrates our commitment to advancing innovative therapeutics that address unmet medical needs,” said Gregory Gorgas, President and Chief Executive Officer of Artelo. “As we progress our lead program, ART26.12, targeting FABP5 to treat pain, we also plan to advance the broader potential of our FABP inhibitor portfolio in other cancers and diseases associated with dysregulated lipid signaling.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL:
- Artelo Biosciences Strengthens Financial Position with New Agreement
- Artelo Biosciences Appoints New Chief Financial Officer
- Artelo Biosciences appoints Mark Spring as Chief Financial Officer
- Artelo Biosciences Enters Cooperation Agreement with Farb
- Artelo announces expanded clinical data to be presented on ART26.12, ART27.13